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o the Editor: 
Terlipressin is a long-acting synthetic analogue of vasopressin, 
emonstrating several potential benefits in the context of living 
onor liver transplantation (LDLT). During the recipient hepatec- 
omy, terlipressin reduces the portal flow. Consequently, it may 
itigate the extent of bowel congestion following portal vein 
lamping. By decreasing portal hyperperfusion and hypertension, 
t protects the graft from further injury and improves renal blood 
ow. All the above described benefits result in decreased morbidity 
nd improved surgical outcomes [1] . 
A meta-analysis of the first three randomized controlled trials 
RCTs) on the perioperative use of terlipressin demonstrated that 
nfusion of terlipressin during LDLT significantly decreased heart 
ate during the anhepatic and neohepatic phases but had no effect 
n the levels of creatinine [1–4] . Since then, three more RCTs have 
een published [5–7] . 
We aimed to track the accumulated evidence of terlipressin 
herapy over time. The primary outcome measure was the man- 
gement of the portal vein pressure. Only RCTs that compared ter- 
ipressin to a placebo in LDLT were selected. Statistical analysis was 
onducted using Review Manager 5.3 software (Cochrane Collabo- 
ation, Oxford, UK). 
Six studies [2–7] including 292 patients were selected from a 
ool of 110 studies. In these studies, 147 and 145 patients were 
ncluded in the terlipressin and placebo treatment groups, respec- 
ively ( Table 1 ). The results were as follows: 
Age, sex, body mass index (BMI), model for end-stage liver 
isease (MELD) score, and graft-to-recipient weight ratio (GRWR) 
ere comparable between the two groups. Moreover, there were 
o significant differences in operative time, estimated blood loss, 
eak intraoperative lactate level, end of surgery lactate level, fresh 
rozen plasma, and colloids infusion between the two groups 
 Table 2 ). 
Peak serum creatinine was significantly lower in the terlipressin 
roup than that in the placebo cohort [mean difference (MD) = - 
.27, 95% confidence interval: -0.52 to -0.02, P = 0.03, I 2 = 75%] 
 Fig. 1 ), while mean arterial pressures (MAP) during the anhep- 
tic and neohepatic phases were significantly lower in the placebo ∗ Corresponding author. 
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.64 to 7.92, P < 0.01, I 2 = 47%; MD = 7.01, 95% CI: 3.47 to 10.55,
 < 0.01, I 2 = 69%, respectively). 
There were significant differences in cardiac output in the an- 
epatic phase and heart rates in the anhepatic and neohepatic 
hases (MD = -0.56, 95% CI: -0.79 to -0.33, P < 0.01, I 2 = 6%;
D = -6.48, 95% CI: -8.69 to -4.27, P < 0.01, I 2 = 10%; MD = -
.82, 95% CI: -11.74 to -1.89, P < 0.01, I 2 = 74%, respectively). 
oreover, portal vein velocity was significantly slower in the ter- 
ipressin group than that in the placebo treatment group and the 
erlipressin group required less doses of inotropes compared to the 
lacebo treatment group ( Table 2 ). 
There were no significant differences in the baseline systemic 
ascular resistance (SVR), cardiac output in the neohepatic phase, 
epatic artery resistive index (HARI) in the first postoperative day, 
rine output, intensive care unit stay, and length of hospital stay 
 Table 2 ). 
No major discrepancies were detected between the results of 
he fixed- and random-effects models. 
The overall quality of the included RCTs ranged from low to 
oderate. Achilles’ heel of the RCTs was performance and detec- 
ion bias calculated. Only the study of Reddy et al. [6] was double- 
linded, while the others were not blinded to the outcome asses- 
ors. 
The present study demonstrated that terlipressin significantly 
ecreased peak serum creatinine, cardiac output in the anhepatic 
hase, portal venous velocity, and heart rate during the anhepatic 
nd neohepatic phases, respectively. On the other hand, MAP dur- 
ng the anhepatic and neohepatic phases was significantly lower 
n the placebo treatment group, and consequently, the need for 
notropes was significantly higher in the placebo treatment group 
han that in the terlipressin group. All the above findings support 
he evidence that the principal hemodynamic effects of terlipressin 
re increased peripheral vascular resistance, decreased cardiac out- 
ut, improved renal blood flow, reduced portal hypertension, and 
elective splanchnic vasoconstriction [8] . 
It is reported that acute kidney injury (AKI) after liver trans- 
lantation as defined by RIFLE (risk, injury, failure, loss of kidney 
unction, and end-stage kidney disease) criteria is a risk factor as- 
ociated with increased morbidity and mortality in the immediate 
ostoperative period [9] . The reported incidence of AKI after de- 
eased liver transplantation ranges widely from 11% to 94% [9] . A a. Published by Elsevier B.V. All rights reserved. 
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Table 1 
Study characteristics. 
Studies Number of 
patients T vs. P 
Age (yr) Male BMI (kg/m 2 ) MELD Terlipressin therapy GRWR ratio 
Mukhtar et al. 
(2011) [2] 
T ( n = 15) 
P ( n = 15) 
50.7 ± 4.9 
49.0 ± 5.8 
13 (86.7%) 
14 (93.3%) 
27.5 ± 6.3 
26.2 ± 3.6 
21.0 ± 3.3 
21.0 ± 2.5 
Bolus 1 mg over 30 min, then 
2 μg/kg/h for 2 d 
1.00 ± 0.14 
0.95 ± 0.13 
Hong et al. 
(2012) [3] 
T ( n = 21) 
P ( n = 20) 
52.3 ± 8.1 
54.0 ± 9.4 
16 (76.2%) 
15 (75.0%) 
NR 17.7 ± 10.5 
15.2 ± 10.0 
1–4 μg/kg/h NR 
Fayed et al. 
(2013) [4] 
T ( n = 40) 
P ( n = 40) 
51.6 ± 6.6 
52.3 ± 4.5 
31 (77.5%) 
33 (82.5%) 
28.1 ± 1.3 
27.6 ± 1.7 
15.6 ± 1.8 
15.5 ± 2.5 
3 μg/kg/h to maintain 
MAP > 65 mmHg and 
SVR < 1300 dyne/s/cm 5 
1.0 ± 0.3 
1.0 ± 0.2 
Ibrahim et al. 
(2015) [5] 
T ( n = 25) 
P ( n = 25) 
43.90 ± 7.01 
45.20 ± 4.84 
NR 27.66 ± 3.09 
26.84 ± 2.98 
14.60 ± 2.56 
14.00 ± 1.12 
1–4 μg/kg/h till POD 4 to 
maintain MAP 65–105 mmHg 
and SVR 1200 dyne/s/cm 5 
NR 
Reddy et al. 
(2016) [6] 
T ( n = 21) 
P ( n = 20) 
49.4 ± 11.2 
47.6 ± 8.9 
17 (81.0%) 
13 (65.0%) 
25.7 ± 4.2 
27.3 ± 4.1 
16 ± 5 
17 ± 7 
2 μg/kg/h for 72 h 0.83 ± 0.38 
0.87 ± 0.28 
Kandil et al. 
(2017) [7] 
T ( n = 25) 
P ( n = 25) 
47.24 ± 5.93 
44.08 ± 9.20 
NR 29.38 ± 3.37 
27.53 ± 4.11 
16.68 ± 4.59 
16.64 ± 4.48 
1–4 μg/kg/h till POD 4 to 
maintain MAP 65–105 mmHg 
and SVR 1200 dyne/s/cm 5 
1.05 ± 0.17 
1.09 ± 0.15 
Pooled 
estimates 
T ( n = 147) 
P ( n = 145) 
Total 292 
T: terlipressin; P: placebo; BMI: body mass index; MELD: model for end-stage liver disease; GRWR: graft-to-recipient weight ratio; NR: nonreported; POD: postoperative day; 
MAP: mean arterial pressure; SVR: systemic vascular resistance. 
Table 2 
Outcome of interests. 
Variables Number of studies Number of patients Estimated effect, 95% CI p value I 2 (%) 
Age (yr) 6 292 MD = 0.11 (-1.41, 1.62) 0.89 0 
Male 4 192 OR = 1.03 (0.51, 2.08) 0.93 0 
BMI (kg/m 2 ) 5 251 MD = 0.55 (-0.02, 1.12) 0.06 12 
MELD 6 292 MD = 0.25 (-0.40, 0.90) 0.45 0 
GRWR 4 201 MD = 0.00 (-0.06, 0.05) 0.94 0 
Operative time (min) 2 80 MD = 0.68 (-0.48, 1.84) 0.25 0 
EBL (mL) 2 121 MD = 147 (-1298, 1591) 0.84 95 
FFP (mL) 2 71 MD = -0.00 (-1.27, 1.26) 1.00 0 
Colloids (mL) 2 71 MD = -534 (-2074, 1005) 0.50 93 
Peak intraoperative lactate (mmol/L) 4 201 MD = 1.41 (-1.03, 3.85) 0.26 80 
End of surgery lactate (mmol/L) 4 201 MD = 1.41 (-1.03, 3.85) 0.26 86 
Creatinine (mg/dL) 5 251 MD = -0.27 (-0.52, -0.02) 0.03 75 
MAP (mmHg) 
Baseline 4 201 MD = 0.45 (-1.48, 2.39) 0.65 0 
Anhepatic 4 201 MD = 4.78 (1.64, 7.92) < 0.01 47 
Neohepatic 4 201 MD = 7.01 (3.47,10.55) < 0.01 69 
SVR (dyne/s/cm 5 ) 
Baseline 4 201 MD = -12.51 (-82.68, 57.66) 0.73 44 
Anhepatic 4 201 MD = 76.36 (-121, 274) 0.45 90 
Neohepatic 4 201 MD = 90 (-127, 307) 0.42 95 
Cardiac output (L/min) 
Baseline 3 151 MD = 0.09 (-0.06, 0.24) 0.23 0 
Anhepatic 3 151 MD = -0.56 (-0.79, -0.33) < 0.01 6 
Neohepatic 3 151 MD = -1.02 (-2.20, 0.16) 0.09 87 
HR 
Baseline 4 181 MD = -1.43 (-4.34, 1.48) 0.34 0 
Anhepatic 4 201 MD = -6.48 (-8.69, -4.27) < 0.01 10 
Neohepatic 4 201 MD = -6.82 (-11.74, -1.89) < 0.01 74 
HARI (s) 
Preoperative 3 180 MD = -0.02 (-0.04, 0.00) 0.13 43 
POD 1 4 221 MD = -0.02 (-0.05, 0.01) 0.12 79 
PVV POD 1 (cm/s) 3 141 MD = -11.97 (-17.12, -6.82) < 0.01 51 
Urine output (mL) 5 242 MD = 0.01 (-1.13, 1.15) 0.99 90 
Need for inotropes 5 242 OR = 0.18 (0.04, 0.86) 0.03 68 
ICU stay (h) 4 162 MD = -0.18 (-0.98, 0.62) 0.66 64 
LOS (d) 3 121 MD = -0.64 (-3.60, 2.32) 0.67 75 
MD: mean difference; OR: odds ratio; CI: confidence intervals; BMI: body mass index; EBL: estimated blood losses; MELD: model for end-stage liver disease; GRWR: graft-to- 
recipient weight ratio; FFP: fresh frozen plasma; HR: heart rate; MAP: mean arterial pressure; SVR: systemic vascular resistance; HARI: hepatic artery resistive index; PVV: 












ecent study still reported an incidence as high as 63% [10] . The re-
orted incidence of AKI after LDLT ranged from 21% to 68% [11] . A
revious meta-analysis reported no significant differences in peak 
erum creatinine [1] . In contrast, the present study demonstrated 
hat the difference was statistically significant. However, it should 
e interpreted with caution, because the definition of AKI varied 2 
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The included studies targeted MAP values between 65 and 
0 mmHg and SVR values between 600 and 1300 dyne/s/cm 5 . 
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Fig. 1. Forest plot depicting serum creatinine and heart rate in anhepatic and neohepatic phases. A: Serum creatinine; B: Heart rate in anhepatic phase; C: Heart rate in 










































mHg during liver transplantation reduces the risk of acute and 
hronic kidney injury [12] . Our study demonstrated no signifi- 
ant differences in SVR values during the anhepatic and neohep- 
tic phases between the two groups. However, the placebo treat- 
ent group had significantly lower MAP values during the anhep- 
tic and neohepatic phases and had a significantly higher need for 
notropes compared to those of the terlipressin group. 
It has been reported that the hallmarks of hyperdynamic circu- 
atory syndrome in cirrhosis are increased cardiac output and heart 
ate and decreased SVR [13] , and that management of type I hepa- 
orenal syndrome with terlipressin and albumin may reduce short- 
erm mortality and can be a bridge over transplantation [14] . The 
resent study demonstrated the positive impact of terlipressin on 
eart rate reduction during anhepatic and neohepatic phases and 
he velocity of portal venous flow on the first postoperative day. 
Reported complications of terlipressin are bradycardia, abdom- 
nal cramps, diarrhea, digital gangrene, and bowel ischemia [15] . 
rom the included studies, only Reddy et al. focussed on this topic. 
hey reported a significantly higher incidence of bradycardia and 
ypertension in patients with terlipressin than that in the placebo 
reatment group. Furthermore, three patients with severe brady- 
ardia required special treatment and were withdrawn from the 
rial. They recommended careful and restraint use of terlipressin 
nd close electrocardiographic monitoring during its use [6] . 
The results of the present study should be interpreted in the 
ontext of its limitations. All the studies included were conducted g
3 
Downloaded for Philip O'Reilly (philip.oreilly@uhb.nhs.uk) at University Hospitals Birmin
For personal use only. No other uses without permission. Cn single centers. The total sample size was small. The definitions 
f outcomes varied among studies, and only one study investi- 
ated the complications of the terlipressin. Analysis of the risk 
ias demonstrated that only the study by Reddy et al. [6] was 
ouble-blinded and none of the rest blinded the assessors of the 
utcomes. Therefore, institutional, underpowered sample, perfor- 
ance, and detection bias may have influenced the results. 
Perioperative use of terlipressin during LDLT demonstrated a 
ignificant and positive effect on MAP and heart rate during the 
nhepatic and neohepatic phases, which translated to significantly 
ower creatinine and less need for inotropes in the early postop- 
rative period. A multicenter RCT adequately powered with prede- 
ned outcomes may shed further light on the topic. 
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